Clinical Trials
2 trialsNCT03600883 2026-03-16
A Phase 1/2, Study Evaluating the Safety, Tolerability, PK, and Efficacy of Sotorasib (AMG 510) in Subjects With Solid Tumors With a Specific KRAS Mutation (CodeBreaK 100)
Amgen
Phase 1/2 Active not recruiting
NCT01928394 2024-12-27
A Study of Nivolumab by Itself or Nivolumab Combined With Ipilimumab in Patients With Advanced or Metastatic Solid Tumors
Bristol-Myers Squibb
Phase 1/2 Completed